Pricing Log in Create free account
Friday 6 November 2026 Export WAT’s income statement to Excel — free account

Waters Corporation

WAT Healthcare Diagnostics & Research

Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024.

Revenue
+120.9%
EPS
−67.0%
Free cash flow
−66.7%
Total debt
+308.2%

Quarter to September 2026, against a year earlier

460.91 7.83 +1.73%
Market cap
$44.5B
P/E
194×
Fwd P/E
81.0×
Dividend yield
—
F-score
5/9
Altman Z
9.63
Beneish M
−2.37
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Waters Corporation 10-Q filed Aug 11, 2026

Fiscal Q2 2026 · Period ended Jul 4, 2026 · Filed · accepted 4:16 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 12, 2026: 6 added · 44 modified; 7 with only figures updated

  1. Modified · Business Overview

    The Company has four operating segments: Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences. Analytical Sciences products and services primarily consist of high-performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLCTMUPLC” and, together with HPLC, referred to as “LC”), mass spectrometry (“MS”), light scattering and field-flow fractionation instruments (Wyatt), and precision chemistry consumable products and related services. Materials Sciences products and services primarily consist of thermal analysis, rheometry and calorimetry instrument systems and service revenue. Biosciences products and services primarily consist of instruments, software and informatics, reagents, and single cell multiomics solutions, supporting the advanced analysis of cell populations for use in fields such as immunology, oncology, and infectious disease research. Advanced Diagnostics products and services primarily consist of a broad range of diagnostic instrumentation, assays, consumables, automation, and informatics that support the detection, identification and drug susceptibility testing of infectious disease organisms.